# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on the de...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 p...
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 p...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 p...
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate o...